mPACT2WO's mRegz™ AirCompliance Simplifies Fenceline Monitoring and Compliance for Operators
LISLE, Ill.--(BUSINESS WIRE)-- mPACT2WO, a Molex business, empowering industrial operators to enhance their daily decisions with easy-to-adopt, early-detection digital solutions, recently showcased its mRegz™ AirCompliance solution in a problem-solving case study with CITGO. This industrial grade early-detection solution enabled CITGO to expand its emissions monitoring program at the Corpus Christi facility, aligning with forthcoming EPA Hazardous Organic NESHAP (HON) requirements.
Adrian Araiza, Corporate Environmental Services Manager at CITGO, explained, 'By utilizing state-of-the-art technology from mPACT2WO, CITGO ensures that our fenceline monitoring not only meets regulatory standards but also sets new benchmarks in safety and environmental responsibility.'
Facing public concerns about the impact of increased emissions following its permit application to expand operations, CITGO sought a precise solution. Partnering with mPACT2WO, CITGO implemented a technology that swiftly and accurately detects emission sources, ensuring early identification and effective response to potential leaks.
mPACT2WO's solution-as-a-service technology focuses on the early detection of emissions, enabling timely corrective actions. By identifying issues before they escalate, this proactive approach helps industrial sites avoid unexpected and exception-prone emissions. The potential benefits include enhanced site safety, compliance validation, risk reduction, and improved operational efficiency.
CITGO successfully implemented mPACT2WO's cutting-edge mRegz™ AirCompliance system, which incorporates advanced photoionization detector (PID) sensors and analytics. This state-of-the-art solution offers unparalleled early detection capabilities, precisely measuring emissions at parts per billion (PPB) levels and accurately detecting leak sources to enable quick root-cause analysis. By leveraging real-time data and critical insights, CITGO identified emission sources beyond the fenceline. This empowered CITGO to propose an innovative alternative monitoring plan that not only met EPA regulatory standards but also helped secure permits by addressing community concerns and enhancing marine terminal throughput.
'By leveraging real-time AI and state-of-the-art sensors with mRegz™ AirCompliance, we were able to identify the sources of the increased emissions for our customer,' said Krishna Uppuluri, vice president and general manager at mPACT2WO. 'Our goal is to help operators optimize emissions monitoring and reduce risks at their plants through real-time data identification. We are proud to have supported CITGO in achieving these objectives.'
The mPACT2WO solution leverages AIoT (Artificial Intelligence of Things) to transform large, noisy datasets into smaller, more actionable insights for operators. By utilizing advanced algorithms and real-time data processing, operators can make informed decisions quickly and efficiently, freeing them from the burden of data management. This empowers boots-on-the-ground teams to detect anomalies early, perform root-cause analysis efficiently, and take timely corrective actions. mRegz™ AirCompliance offers a holistic solution for fenceline monitoring, LDAR (leak detection and repair), tank farms, pipelines, terminals, process safety, unmanned remote sites and other community-partnership initiatives.
For more information on how mPACT2WO's emissions monitoring solution can help process industries augment compliance for EPA HON standards, visit https://mpact2wo.com/solution-air-compliance. To learn more about mPACT2WO's suite of AIoT-enabled early detection solutions, visit https://mpact2wo.com/.
About mPACT2WO, a Molex Business
mPACT2WO, a Molex business, empowers industrial operators to enhance their daily decisions with easy-to-adopt, early-detection digital solutions. By bringing the simplicity and usability of consumer apps to industrial operations, the operator-first approach accelerates boots-on-the-ground transformation to enhance operational efficiency, compliance and safety while reducing over-monitoring and over-maintenance. The solutions are enabled by NextGen sensors, intelligent data analytics, and operator-trusted insights with operator-familiar work processes. mPACT2WO solutions for emissions and corrosion monitoring helps industrial sites reduce emissions, enhance process safety, and avoid unexpected corrosion and unplanned maintenance. For more information, visit mpact2wo.com or connect with us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Karen Rudolf: Transforming Lives with "W"holistic Healing and the Tranquil SOULutions Clarity Tool(TM)
SARASOTA, FL / / June 2, 2025 / In the bustling landscape of personal transformation and holistic wellness, Karen Rudolf stands out as a beacon of resilience and empowerment. A former nurse turned transformational coach and author, Karen is dedicated to guiding individuals toward profound shifts in perception, inner clarity, and authentic living through her newly launched Tranquil SOULutions Clarity Tool™. A "W"holistic Approach" to Healing Karen's journey into "w"holistic healing was sparked by deep frustration with traditional Western medicine's symptom-based approach. She recognized early on that true healing requires addressing root causes rather than merely managing symptoms. Driven by personal and family challenges, Karen has embraced modalities such as Neuro-Linguistic Programming (NLP), HeartMath, and trauma-clearing techniques to "w"holistically align the mind, body, and spirit," she says. "My personal experiences showed me the interconnectedness of physical health, emotional well-being, and spiritual resilience," Karen shares. "I developed the Tranquil SOULutions Clarity Tool™ to facilitate deep introspection and authentic self-discovery, supporting individuals to move beyond limiting beliefs toward empowered living." Shifting Perceptions for Lasting ChangeThe Tranquil SOULutions Clarity Tool™ is not just another self-help app-it's a personalized journey designed to shift users' perceptions through structured reflection and intuitive guidance. By harnessing insights from quantum physics, neuroscience, and Jungian psychology, Karen's innovative tool supports users in identifying and overcoming emotional barriers, fostering greater clarity and self-awareness. As Karen emphasizes, "When you change the way you look at things, the things you look at change. This tool supports that powerful shift." Empowerment Through Resilience and MindsetKaren's compelling life story highlights the critical role of mindshifting in healing and resilience. Her approach underscores the transformative power of viewing challenges as opportunities for growth rather than setbacks. "My experiences taught me that vulnerability and authenticity are strengths, not weaknesses," Karen explains. "Embracing these aspects allows us to truly empower ourselves and those around us." Practical Frameworks for Modern ChallengesOne of Karen's hallmark techniques, the "Stop, Change, Shift" butterfly method, exemplifies her practical, accessible approach to stress management. This mindfulness practice enables individuals, especially overwhelmed entrepreneurs, to quickly recalibrate their emotional state, enhancing productivity and well-being. Early users of the Tranquil SOULutions Clarity Tool™ have already praised its effectiveness. Rosemary, a former executive at UNICEF, described the tool as "life-changing, providing deep clarity and actionable insights immediately." Serving the Overwhelmed EntrepreneurKaren's coaching specifically addresses entrepreneurs, particularly women aged 40-65, who face overwhelming demands in their professional and personal lives. Her methods provide these individuals with clarity, emotional balance, and an authentic path to achieving sustainable personal and professional success. "My goal is to support individuals to reclaim their inner strength and clarity," Karen says. "Everyone deserves to experience life through a lens of empowerment and joy." To experience the Tranquil SOULutions Clarity Tool™ or to connect with Karen Rudolf directly, visit or reach out via her LinkedIn profile. About Karen RudolfKaren Rudolf, the founder of Tranquil SOULutions™, is a transformational coach, nurse, bestselling author, and international speaker. With expertise in neuroscience, quantum physics, NLP, and trauma-informed practices, Karen empowers clients to achieve profound personal transformation and holistic well-being. Media Contact:Name: Karen RudolfEmail: Karen@ SOURCE: Tranquil Soulutions View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ('Eupraxia' or the 'Company') (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the 'Meeting') held on June 2, 2025. Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company's board of directors (the 'Board') at the Meeting and listed in the Company's Management Information Circular dated April 25, 2025, were elected. The directors will remain in office until the next annual meeting of shareholders, or until their successors are elected or appointed. The results of the vote on the election of the Board are as follows: Board of Directors Votes in Favour Votes Withheld Number of Votes Percentage (%) Number of Votes Percentage (%) James A. Helliwell 17,880,699 99.997 505 0.003 Simon Pimstone 16,123,679 90.171 1,757,475 9.829 Richard M. Glickman 17,879,949 99.993 1,255 0.007 Paul Geyer 17,680,609 98.878 200,595 1.122 John Montalbano 17,876,501 99.974 4,703 0.026 Michael Wilmink 17,876,508 99.974 4,696 0.026 Joseph Freedman 17,880,699 99.997 505 0.003 The other items of business at the Meeting were to (i) re-appoint KPMG LLP as the auditor of the Company for the ensuing year and to authorize the Board to fix the remuneration of the auditors; (ii) approve the Company's 2025 Omnibus Incentive Plan; and (iii) approve the re-pricing of certain stock options previously granted to certain non-executive employees, none of which are insiders of the Company, under the Company's amended and restated stock option plan. All such items of business were passed by the shareholders at the Meeting. About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas. Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: Notice Regarding Forward-looking Statements and Information This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", 'suggests', "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements in this news release include statements regarding the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's products, and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy its our product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the potential impact of tariffs on the cost of the Company's API and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ ( and EDGAR ( Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise. For investor and media inquiries, please contact:Danielle Egan, Eupraxia Pharmaceuticals Inc.778.401.3302degan@ or Kevin Gardner, on behalf of:Eupraxia Pharmaceuticals Inc.617.283.2856kgardner@ SOURCE Eupraxia Pharmaceuticals in to access your portfolio
E&E News
an hour ago
- E&E News
EPA resumes internal reshuffle planning
EPA is proceeding with some aspects of its reshuffling following a court order freezing reorganization and layoff plans. That includes some program managers continuing interviews with staffers — primarily in the agency's research office — who applied for reassignments to other offices, according to an internal email shared with POLITICO's E&E News. 'EPA is complying with the court's preliminary injunction,' the agency's press office said in response to questions about resuming reassignment interviews. 'In line with the court's order and guidance received by the Department of Justice, EPA is moving forward with only reorganization planning activities.' Advertisement A judge in the U.S. District Court for the Northern District of California issued on May 22 a sweeping injunction that put a pause on dozens of agencies' reorganization or reduction-in-force plans, declaring such plans require authorization from Congress before continuing. The government has appealed the ruling.
